Design Therapeutics | 8-K: Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio
Design Therapeutics | 8-K: Current report
Design Therapeutics | 8-K: Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Design Therapeutics | DEFA14A: Others
Design Therapeutics | DEF 14A: Definitive information statements
Design Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Design Therapeutics | 8-K: Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
Design Therapeutics | 8-K: Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Design Therapeutics | 8-K: Current report
Design Therapeutics | 8-K: Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
Design Therapeutics | 8-K: Current report
Design Therapeutics | 8-K: Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
Design Therapeutics | DEFA14A: Others
Design Therapeutics | DEF 14A: Definitive proxy statements
Design Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Design Therapeutics | 8-K: Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Design Therapeutics | 8-K: Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Design Therapeutics | 8-K: Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
Design Therapeutics | 8-K: Current report
Design Therapeutics | 8-K: Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
No Data
No Data